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Abstract
Childhood cancer survivors (CCS) experience significant
morbidity due to treatment- related late effects and benefit
from late-effects surveillance. Adherence to screening
recommendations is suboptimal. Survivorship care programs
often struggle with resource limitations and may benefit from
understanding institution-level financial outcomes associated
with patient adherence to justify programmatic development
and growth. The purpose of this study is to examine how CCS
adherence to screening recommendations relates to the cost of
care, insurance status, and institution-level financial outcomes.
A retrospective chart review of 286 patients, followed in
a structured survivorship program, assessed adherence
to the Children’s Oncology Group follow-up guidelines by
comparing recommended versus performed screening
procedures for each patient. Procedure cost estimates were
based on insurance status. Institutional profit margins and
profit opportunity loss were calculated. Bivariate statistics
tested adherent versus nonadherent subgroup differences
on cost variables. A generalized linear model predicted the
likelihood of adherence based on cost of recommended
procedures, controlling for age, gender, race, and insurance.
Adherence to recommended surveillance procedures was
50.2%. Nonadherence was associated with higher costs
of recommended screening procedures compared to the
adherent group estimates ($2,469.84 vs. $1,211.44). Failure
to perform the recommended tests resulted in no difference
in reimbursement to the health system between groups
($1,249.63 vs. $1,211.08). For the nonadherent group, this
represented $1,055.13 in “lost profit opportunity” per visit
for patients, which totaled $311,850 in lost profit opportunity
due to nonadherence in this subgroup. In the final model,
nonadherence was related to higher cost of recommended
procedures (p < .0001), older age at visit (p = .04), Black race
(p = .02), and government-sponsored insurance (p = .03).
Understanding institutional financial outcomes related to
patient adherence may help inform survivorship care programs
and resource allocation. Potential financial burden to patients
associated with complex care recommendations is also
warranted.
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INTRODUCTION

Over 80% of children diagnosed with cancer are
cured of their disease resulting in more than 350,000
childhood cancer survivors (CCS) living in the USA
[1, 2]. As a consequence of exposure to curative

Implications

Practice: Efforts to improve adherence to survivorship care guidelines among childhood
cancer survivors should consider addressing the
financial burden associated with costs of care,
such as assisting patients in understanding, being
prepared for, and managing health care costs.
Policy: Understanding the ways in which patient
adherence is related to the cost of care and financial burden to patients, and financial impact
on healthcare institutions, may be important to
building institutional support for survivorship
care programs and resources for optimizing
adherence rates.
Research: Further evaluation of the ways in
which financial factors have an impact at the patient level and at the institution level may be important to building programs that will support
optimal patient adherence and survivorship care.
treatment modalities, such as chemotherapy, radiation, and surgery, CCS experience high rates of
morbidity and mortality due to secondary health
problems [3]. As many as 95% of CCS will develop
a chronic disease, with over 80% developing a severe, disabling, or life-threatening condition, due
to treatment effects [4, 5]. Despite the Children’s
Oncology Group (COG) development of exposureand risk-based screening guidelines for the long-term
follow-up of CCS [6], adherence to posttreatment
screening recommendations remains suboptimal
even among high-risk survivors [7]. Less than a third
of CCS report receiving follow-up care that is based
on their cancer history [8]. Understanding how patient adherence relates to hospital-level finances may
be critical to establishing survivorship care programs
and optimizing the long-term follow-up and health
outcomes of this at-risk group.
Survivorship programs that promote evidencebased surveillance of late effects lead to early
detection, referral, and treatment. Program activities include providing patients with up-to-date
information about late effect, educating about
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care recommendations, and developing and
implementing personalized follow-up plans [9].
Despite the well-recognized need of long-term
follow-up care for CCS, programs are often
limited by inadequate resources and understaffing.
Decisions within health care systems about resource
allocation are influenced by revenue generation.
Survivorship care can be labor and time intensive
and, in the USA, reimbursement for survivorship
visits and financial remuneration is limited compared to other service lines. While some services are
revenue generating (e.g., surveillance testing), many
are not (e.g., care coordination), and the economic
case for program benefit is considered tenuous [10,
11]. Many cancer-treating institutions have limited
capacity to support the long-term follow-up of CCS
patients [12]. Financial constraints and lack of administrative support are cited as barriers to the
adoption and growth of survivorship programs [13].
Developing and sustaining such programs typically
requires financial backing and support from the institution for services, staff, and space allocation [14].
It is argued that the cost evaluation of survivorship
programs is essential to justify program value and
to garner administrative buy-in and institutional support, but this has been limited to date [15, 16].
We previously described rates of adherence to
survivorship care recommendations, based on COG
guidelines, within a structured, long-term follow-up
clinic for CCS [11–13, 17]. Given the importance
of surveillance and the vital role of survivorship
programs in providing cohesive long-term care for
survivors, these secondary analyses from the same
data set compared institution-level financial outcomes between adherent and nonadherent patient
subgroups regarding reimbursement, profit margin,
and profit opportunity loss. We also examined how
the cost of care and insurance status related to adherence to survivorship care recommendations,
controlling for relevant covariates. To our knowledge, this is the first study to examine differences
in institutional financial outcomes based on patient
adherence to COG guidelines, including health
system-level profit margins. Results from this analysis may inform programmatic decision-making
within health care systems and drive institution- or
policy-level changes to support clinical efforts to improve patient adherence and the long-term survivorship care of CCS.
METHODS

This study was conducted within the CCS long-term
survivorship program within the Division of
Pediatric Hematology/Oncology and Stem Cell
Transplant at Cohen Children’s Medical Center,
Northwell Health. All study procedures were approved by the Institutional Review Board and the
Cancer Services Scientific Review Committee of the
Northwell Health System.
TBM

This was a secondary analysis of data collected
from a retrospective chart review of 286 patients followed in a structured, long-term follow-up program
for CCS housed within a large, integrated medical
center in the New York area. Within this program,
patients are seen in a medical office, off-campus
from the main children and adult hospitals. Clinic
visits include a review of late-effect risks and recommended screening procedures with a physician or
nurse practitioner that specializes in survivorship
care, a laboratory evaluation (at an on-site phlebotomy center), meeting with a nurse coordinator
to facilitate the scheduling and performance of
screening procedures (e.g., echocardiography and
pulmonary function testing breast magnetic resonance imaging [MRI]), and meeting with a social
worker to address psychosocial concerns. Screening
recommendations and referrals are generally based
on the COG guidelines [18].
Study population

All CCS followed in the survivorship program were
eligible for the study. Patients are eligible to be seen
in the program once they are 3 years from the completion of their cancer therapy and disease free. The
program provides lifelong follow-up care.
Data collection

This study included secondary analysis of data
obtained in a retrospective review of the medical records of all CCS seen at least once in the survivorship
program between January 1, 2010 and December
31, 2012. Data included standard sociodemographic
information, cancer history and treatment exposure,
and insurance coverage (categorized into three
groups: commercial insurance, an “underinsured”
group representing Medicaid or no insurance, and
unknown). Preliminary analyses did not identify
differences between subgroups with Medicaid, no
insurance (self-pay), and unknown in rates of adherence (p = .48). For each patient, survivorship care
documentation included recommended and completed procedures.
Based on COG guidelines, procedures included the
following screening tests: echocardiography, electrocardiograms, pulmonary function tests, dual-energy
x-ray absorptiometry scans (DXA) scans, breast MRI,
breast mammography, hearing tests, fasting blood
work, nonfasting blood work, and urinalysis. In addition, we included breast ultrasound, as this is often
a patient-preferred screening modality to mammography, and thyroid ultrasound, as this was routinely
recommended in our survivorship practice despite
it not being specifically recommended by the COG
guidelines. Financial data about procedure costs and
reimbursement to the health system were obtained to
evaluate the projected and actual costs of procedures
(recommended and performed) and reimbursement
to the health system based on insurance status.
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Variable definitions

Adherence
Adherence to a given recommendation was defined as completing the screening procedure within
12 months of the recommendation, given that most
survivorship visits and screening recommendations
occur on an annual basis. If patients had survivorship visits more frequent than annually, adherence
was defined as having the screening test performed
prior to the next visit for fasting blood work,
nonfasting blood work, and urinalysis. Adherence
is reported at the patient level (two groups; adherent vs. nonadherent) and at the visit level by
procedure. At the patient level, nonadherence was
defined as the failure to complete any one recommended procedure such that patients that completed some but not all recommendations were
still classified as nonadherent. Patients that were
recommended to complete more than one procedure within the study time frame were defined as
adherent only if they completed all recommendations. Adherence at the visit level was also reported
as it was theorized that patients’ adherence may
change over time or vary depending on the type
of procedure recommended, and this allowed us
to model factors with varying effects on adherence
across visits.
Survivorship care costs
Financial records of the Northwell Health System
during the 3 year time frame were reviewed to
quantify the cost and reimbursement for screening
tests provided that were directly related to survivorship care within the survivorship program. Four
variables were calculated. Two variables described
procedures that were recommended for each patient: the projected cost of recommended procedures (i.e., fee estimate to the health system) and the
reimbursement amount for recommended procedures (i.e., projected value the health system would
receive). Two additional variables described procedures that were completed by each patient: the
cost of performed procedures (i.e., fee estimate for
performed procedures to the health system) and the
reimbursement amount for performed procedures
(i.e., the value the health system receives for each
test performed). Variables estimating the cost of
and reimbursement for recommended procedures
followed COG guidelines for surveillance testing
for each patient, irrespective of whether patients
completed the procedure. Variables representing
the cost of and reimbursement amount for performed procedures depended on patient adherence
and whether the procedure was actually performed.
Following this, variables were calculated to estimate the institutional profit when patients were adherent and, conversely, the “lost profit opportunity”
when patients were nonadherent. The profit of performed procedures was calculated by subtracting

the cost of performed procedures from the reimbursement of performed procedures. The health
system’s lost profit opportunity was defined by first
calculating what the profit would have been if all recommended procedures were completed for each
patient and subtracting the profit that was actually
made from the procedures that were done. Thus,
this opportunity loss represented the profit loss associated with nonadherence.
Data analysis

Descriptive statistics were used to describe the study
population, adherence rates, costs of recommended/
performed procedures, and reimbursement.
Bivariate analyses identified differences between
adherent and nonadherent patient subgroups based
on sociodemographic characteristics and cost variables, including group differences in health systemlevel profit and profit opportunity loss. Adherence
was analyzed separately for all recommended surveillance tests with the exception of breast MRI,
breast ultrasound, and mammography due to the
small number of these tests recommended in this
study group. Analyses used independent samples
t-tests and chi-square to test bivariate associations.
Understanding that our preliminary analyses testing
bivariate associations would be unable to account
for nonindependence of data, a generalized linear
model (GLM) was used to predict likelihood of adherence using a generalized estimating equation
(GEE) to derive parameter estimates as detailed
below. In the GEE models, we used binary distribution and logit link function for logistic regression. We used TYPE=EXCH option to specify an
exchangeable working correlation structure; the
CORRW option to request the working correlation
matrix and LOGOR=fullclust for log odds ratio
(OR); and quasi-information criterion was used for
goodness of fit.
To evaluate associations between survivorship
care cost and adherence, while controlling for relevant covariates, such as age and cancer diagnosis,
multivariate models were specified with adherence as the outcome variable. A GLM was used to
predict the likelihood of adherence using a GEE
to derive parameter estimates as this type of model
is appropriate when there is nonindependence
within the covariance structure such that correlated data due to patients having multiple visits
were accounted for. Adherence measured at the
visit level was used as the outcome variable in the
final multivariable model in order to evaluate factors related to adherence that vary within patients
over time (e.g., age). The visit-level cost of recommended procedures was included as a predictor
of adherence as a two-group categorical variable
based on a median split ($400). All models controlled for age at visit, gender, race/ethnicity, and
insurance status.
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RESULTS

The charts of 286 patients seen in the survivorship clinic for long-term follow-up care after childhood cancer were reviewed, representing a total of
542 visits during the 3 year period. Study sample
characteristics, diagnosis, and treatment data are in
Table 1. The average age of diagnosis was 7.9 years;
50.4% were male and 19.6% were of Medicaid or selfpay insurance status. The overall rate of adherence
to recommended procedures was 50.18% (272 out
of 542 recommended procedures), with 74.2% of patients adherent to all recommended procedures (212
out of 286 patients).
Patient adherence to screening recommendations
varied based on several sociodemographic and medical factors (Table 2). In a separate bivariate analysis, classification into the nonadherent group was
associated with older age at visit (Means = 18.0 vs.
16.5 years old), identifying as Black (vs. Other), and
being underinsured (i.e., Medicaid or no insurance;
vs. commercial, private, or unknown insurance).
Age at diagnosis, gender, and history of radiation
therapy (RT), anthracycline, and transplant was not
related to recommendation adherence. Rates of adherence were similar across recommended surveillance tests (p > .05).
Mean costs of recommended and performed procedures, including health system-level profit and
profit opportunity loss, and differences between
adherent and nonadherent groups are reported in
Table 3. The average cost of recommended procedures for the adherent group was $1,211.44
(standard deviation [SD] = $1,272.27), whereas
the projected cost of recommended procedures for
the nonadherent group was significantly higher at
$2,469.84 (SD = $2,100.68). Thus, the nonadherent
group was characterized by greater potential costs
at the institution level if they were to undergo all recommended procedures compared to the adherent
group. There was no difference between adherent
and nonadherent groups in the reimbursement for
procedures performed, which averaged just over
$1,200 for each group (i.e., $1,211.08 in the adherent group and $1,249.63 in the nonadherent
group).
Further comparison of the adherent and
nonadherent groups evaluated the degree of profit
and profit opportunity loss at the institution level.
It was estimated that, per visit, the health system received an average of $850.52 (SD = $1,135.23) in
profit per visit for patients in the adherent group.
Conversely, the nonadherent group’s recommended
care included higher cost procedures with a greater
potential profit margin for the health system. It was
estimated that the health system would have received an average of $1,932.81 (SD = $1,924.22)
in profit per visit if these patients had completed
all recommended procedures. However, because
they were not fully adherent, the profit per visit
TBM

Table 1 | Patient characteristics (N = 286)

Patient characteristics

Mean (range)

Average age at diagnosis
7.9 (0–23)
Gender
Male
Female
Race
Asian
Black
Hispanic
White
Other
Unknown
Insurance
Commercial
Medicaid or self-pay
N/A
Cancer diagnosisa
Leukemiab
Lymphoma
Bone and soft tissue tumors
Embryonal tumors
Others
Treatment
Chemotherapy (CT) only
Radiation therapy (RT) only
Both CT and RT
Neither CT nor RT
Total visits at survivorship clinic
1
2
3
4
5
Type of treatment
Alkylator
Carboplatin
Cisplatin
Etoposides
Antimetabolites
Dactinomycin
Vincaalkyloids
Anthracycline
Corticosteroids
Transplant

n (%)

142 (49.6%)
144 (50.4%)
20 (7.0%)
29 (10.1%)
30 (10.5%)
112 (39.2%)
10 (3.5%)
85 (29.7%)
177 (61.9%)
56 (19.6%)
53 (18.5%)
124 (43.4%)
78 (27.3%)
20 (7.0%)
50 (17.5%)
14 (4.9%)
165 (57.7%)
2 (0.7%)
117 (40.9%)
2 (0.7%)
119 (41.6%)
92 (32.2%)
64 (22.4%)
8 (2.8%)
3 (1.0%)
186 (65.0%)
18 (6.3%)
33 (11.5%)
104 (36.4%)
158 (55%)
23 (8.0%)
230 (80.4%)
216 (75.5%)
185 (64.7%)
16 (5.6%)

a

Brain tumor survivors were managed in a separate brain tumor program.
Includes B acute lymphoblastic leukemia (B-ALL), T acute lymphoblastic leukemia
(T-ALL), acute myelogenous leukemia (AML), and chronic myelogenous leukemia
(CML).

b

for the nonadherent group averaged $877.68
(SD = $1,411.68) similar to that of the adherent
group. Thus, the average lost profit opportunity
per visit for patients within the nonadherent group
was $1,055.13 (SD = $1,545.74; i.e., $1,932.81 −
$877.68). The total lost profit to the health system
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Table 2 | Differences between adherent and nonadherent patient groups: sociodemographic and medical factors

Patient characteristics
Average age at visit (years)
Gender
Male
Female
Racea
Asian
Black
Hispanic
White
Other
Unknown
Insurancea
Commercial
Medicaid or self-pay
N/A
Cancer diagnosis
ALL
Lymphoma
Bone and soft tissue tumors
Embryonal tumors
Others
Treatment
Chemotherapy (CT) only
Radiation therapy (RT) only
Both CT and RT
Neither CT nor RT
Total visits
1
1
2
3
4
5
Type of treatment
Alkylator
  Yes
   No
Carboplatin
  Yes
   No
Cisplatin
  Yes
   No
Etoposides
  Yes
   No
Antimetabolites
  Yes
   No

Adherent group (n = 272 visits)

Nonadherent group (n = 270 visits)

M (SD)
or n (%)

M (SD)
or n (%)

16.5 (6.9)

18.0 (7.3)

145 (52.7%)
127 (47.6%)

130 (47.3%)
140 (52.4%)

19 (46.3%)
19 (35.9%)
28 (49.1%)
124 (55.6%)
13 (65.0%)
69 (46.6%)

22 (53.7%)
34 (64.1%)
29(50.9%)
99 (44.4%)
7 (35.0%)
79 (53.4%)

185 (55.1%)
43 (39.5%)
44 (45.4%)

151 (44.9%)
66 (60.5%)
53 (54.6%)

128 (53.6%)
57 (39.9%)
19 (46.3%)
57 (57.0%)
11 (57.9%)

111 (46.4%)
86 (60.1%)
22 (53.7%)
43 (43.0%)
8 (42.1%)

159 (50.5%)
1 (50.0%)
111 (49.8%)
2 (50%)

156 (49.5%)
1 (50.0%)
112 (50.2%)
1 (50%)

p value

.0106
.2295

.0825
(.028)b

.0105

.0451

.9989

<.001
37 (31.1%)
80 (43.5%)
125 (65.1%)
24 (75.0%)
6 (40.0%)

82 (68.9%)
104 (56.5%)
67 (34.9%)
8 (25.0%)
9 (60.0%)
.5626

179 (49.3%)
93 (52.0%)

184 (50.7%)
86 (48.0%)

25 (58.1%)
247 (49.5%)

18 (41.9%)
252 (50.5%)

35 (50.0%)
237 (50.2%)

35 (50.0%)
235 (49.8%)

99 (49.0%)
173 (50.9%)

103 (51.0%)
167 (49.1%)

155 (51.3%)
117 (48.7%)

147 (48.7%)
123 (51.3%)

.2769

.9736

.6733

.5516
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Table 2 | Continued

Dactinomycin
  Yes
   No
Vincaalkyloids
  Yes
   No
Anthracy
  Yes
   No
Corticosteroids
  Yes
   No
Transplant
  Yes
   No
Annual visit
  Yes
   No

Adherent group (n = 272 visits)

Nonadherent group (n = 270 visits)

M (SD)
or n (%)

M (SD)
or n (%)

p value

.1779
28 (59.6%)
244 (49.3%)

19 (40.4%)
251(50.7%)

217 (49.3%)
55 (53.9%)

223 (50.7%)
47 (46.1%)

208 (49.3%)
64 (53.3%)

214 (50.7%)
56 (46.7%)

173 (49.0%)
99 (52.7%)

180 (51.0%)
90 (47.6%)

21 (58.3%)
251 (49.6%)

15 (41.7%)
255 (50.4%)

208 (47.6%)
64 (60.95%)

229 (52.4%)
41 (39.05%)

.4021

.4343

.4543

.3115

.0140

ALL acute lymphoblastic leukemia; SD standard deviation.
a
High rates of missing data were observed for Race and Insurance, which was adjusted for by including the categories “Unknown” and “N/A” into group difference tests,
respectively.
b
p value for Black versus all other races/categories

Table 3 | Differences between adherent and nonadherent patient groups: economic factors for the health care systema

Adherent group
(n = 272 visits)

Nonadherent group
(n = 270 visits)

p value

a

Economic factors
Expected reimbursement to the health system based on
procedures recommended ($)
Actual reimbursement to the health system based on procedures
performed ($)
Expected cost to the health system procedures recommended ($)
Actual cost to the health system of procedures performed ($)
Expected profit based on recommended proceduresb ($)
Actual profit for performed proceduresc ($)
Lost opportunityd ($)

1,211.4

2,469.8

<.0001

1,211.4

1,249.6

.7529

362.0
362.0
849.4
849.4
0

537.0
372.0
1,932.8
877.6
1,055.1

<.0001
.4229
<.0001
.8053
<.0001

a

Reported in U.S. dollars ($).
Expected profit for recommended procedures = expected reimbursement of recommended procedures − expected cost of recommended procedures.
Actual profit for performed procedures = actual reimbursement of performed procedures − actual cost of performed procedures.
d
Lost opportunity = expected profit for recommended procedures − actual profit for performed procedures.
b
c

due to nonadherence was $311,850 for these data
set representing patient visits within this 3 year time
period.
Multivariate model predicting adherence

Results of the multivariate analysis are shown in
Table 4 (GEE model fit criteria, quasi-information
criterion = 691.80). The cost of recommended
procedures was found to be a highly significant
predictor of adherence (p < .001). Patients with
recommended procedures that exceeded $400
TBM

(median cost) were less likely to be adherent than
those with recommended procedures that cost less
than $400 (OR = 0.32; 95% confidence interval [CI]:
0.215 to 0.464). Evaluation of covariates also indicated that all factors associated with adherence in
bivariate analysis remained significant in this overall
model. Older age at visit (OR = 0.97; 95% CI: 0.943
to 0.998), Black racial/ethnic identity (OR = 0.47;
95% CI: 0.232 to 0.902), and underserved insurance status (OR = 0.59; 95% CI: 0.361 to 0.955) related to greater likelihood of nonadherence. Cancer
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Table 4 | Multivariate model predicting adherent versus nonadherent subgroup membership (N = 542)

Patient Characteristics
a

Black race (vs. all other races)
Underserved insurance (vs. commercial insurance)a
Age at visit
Male gender (vs. female gender)
Cost of recommended procedures ≥$400 (vs. ≤$400)b

Estimate coefficient

p value

Odds ratio

95% confidence interval

−0.7827
−0.5325
−0.0305
0.1250
−1.1517

.0240
.0319
.0360
.5450
<.0001

0.4572
0.5872
0.9699
1.1332
0.3161

(0.2317, 0.9019)
(0.3610, 0.9550)
(0.9426, 0.9980)
(0.7559, 1.6988)
(0.2154, 0.4639)

a

High rates of missing data were observed for race and insurance, which was adjusted for in the model by including missing data categories in the categorical variables.
$400 was the median value of the cost of recommended procedures at the visit level.

b

diagnosis was not included in the multivariate model
due to multicollinearity with age and cost of recommended procedures.
DISCUSSION

Survivors of childhood cancer are at increased
risk for chronic health conditions and secondary
malignancies that require long-term follow-up surveillance. Adherence to exposure- and risk-based
screening guidelines improves detection of late effects and can be cost effective [5, 15, 19]. We found
that nonadherence to screening procedures among
CCS resulted in lowered reimbursement amounts to
the health system, which we termed “lost profit opportunity.” Patients were less likely to be adherent
to higher cost procedures. Other factors relating
to nonadherence included older age, identifying
as Black, and being underinsured. Improving CCS
adherence to screening recommendations is an
important undertaking. Ultimately, it will require
broad efforts both at the patient level, by reducing
barriers and targeting those patients most at risk for
nonadherence, as well as at the system level through
the allocation of resources and institutional support
for survivorship care programs, such as patient navigators and financial counselors.
Impact to the health system

Caring for CCS requires a coordinated, multidisciplinary approach and involves screening that utilizes
multiple modalities, including blood tests, radiology
tests, and evaluation by subspecialists. Each of these
health care utilization encounters provides an opportunity for financial profit to the health care institution. When CCS are nonadherent to screening
recommendations, this results in fewer health care
encounters and, therefore, represents a “lost profit
opportunity” for the health system. In this study, we
found that the total lost profit to the health system
due to nonadherence was $311,850 for 286 CCS
during the 3 year time frame of this study (2010–
2012). This translates to approximately $348,700
in today’s dollars, adjusting for inflation from 2012
to 2019.[20] It is notable that survivorship care
programs have been characterized as limited in their
revenue-generating opportunity. However, findings
suggest opportunity for some financial benefit to the

hospital. Clearly, hospitals have both clinical and financial incentives to improve adherence and profit
margin. Despite established care guidelines, clinicians treating CCS may be in positions of needing
to justify the value of survivorship program. This
is consistent with research citing program development and resource factors (e.g., hiring staff and
finding space) as the most commonly cited need
among survivorship care teams [14]. Greater investment in survivorship programs that increase clinic
resources, allowing for supportive care efforts to address patient-level access barriers, may translate to
improved patient adherence and increased profit.
The association between lost profit opportunity
and adherence amongst CCS provides an opportunity for mutual benefit. A modest investment of resources on the part of the health system to improve
adherence amongst CCS can provide a positive return on investment. It is, thus, important to clearly
identify the specific barriers to adherence among
CCS, and we have begun a follow-up study of our
survivorship population to attempt to do so. In the
interim, it is reasonable to speculate that improving
access to screening tests (e.g., through improved
patient navigation, care coordination that provides
facilitated scheduling, and ease of transportation
to the testing site) would likely improve adherence.
Communication between survivorship teams and
health system administration surrounding the barriers to adherence may be able to relieve some of
those barriers with a minimal investment of time
and resources, thereby improving the health and
quality of life in the CCS and providing a return on
investment for the health system.
Notably, access to care and patient adherence
exists within the broader social ecology of health
and health care in the USA, which includes individual, family, and societal factors, payer systems,
policy, and government structures [21]. In this study,
factors specific to our institution (e.g., scheduling
problems) or location (e.g., commuting challenges)
may have impacted patient adherence. Among
CCS, adherence to surveillance recommendations is influenced by geographic location and the
availability of providers and cancer care settings
[22]. Data were also collected prior to many of the
provisions mandated by the Affordable Care Act
(ACA). Although research shows that the ACA has
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substantially decreased the number of uninsured individuals in the USA, changes vary by state and the
affordability of health care, and financial toxicity
effects of cancer treatment, in particular, are still a
concern [23–26]. As changes continue to occur with
respect to health care delivery and financing, further
research is needed to understand the impact on access to care among CCS [27]. Analysis of the cost effectiveness of COG guidelines within the context of
health care system changes, including downstream
health care costs and financial burden to patients,
may be important for refining recommendations,
developing targeted approaches to support patient
adherence, and guiding the long-term follow-up care
of CCS [15, 28, 29]. Representing the pharmaceutical industry, insurance providers, oncologists, and
patient advocates, Zafar et al. present potential solutions for the rising cost of cancer care, targeting
multiple levels, such as increasing price awareness
among providers, the inclusion of cost in treatment
discussions with patients, and policy interventions
(e.g., value-based contracting), citing that all stakeholders must be involved to ensure high-value care
[30]. Although we showed modest profit margins
and profit opportunity related to adherence within
our survivorship care program, addressing these
broader challenges is critical as institutions make decisions about resource allocation and investment in
clinical services.
Impact to the patient

We previously identified suboptimal rates of adherence to personalized, risk-based screening recommendations for CCS [17]. In this follow-up study, we
found several patient-level factors correlated with
nonadherence, including older age, identifying as
Black, and government-sponsored insurance. Other
patient factors predicting nonadherence among
CCS include knowledge of treatment exposures,
perception of symptoms and risk, motivation, affect,
and provider influences [31–33].
We also found the cost of care at the hospital level distinguished survivors’ likelihood of
being adherent even when controlling for other
sociodemographic factors and insurance type. There
appeared to be a financial “threshold” of ~$1,200
that characterized costs in both the adherent and
nonadherent groups, above which the nonadherent
group was noncompliant with recommended care.
Recommended care that includes more procedures or higher cost procedures likely represents
a greater burden to patients, such as the time, effort, and/or finances required. Trends over the last
several decades have shown increased cost sharing
between patients and payers, including increasing
deductibles, increasing premiums, coinsurance,
greater copayments, and reduced affordability
[30]. Combined with increasing costs of medication
and treatment, it is well documented that shifts in
TBM

payment structures have yielded greater financial
stress for cancer survivors [34]. Among CCS, higher
out-of-pocket medical costs and the experience of
personal financial problems are associated with
delaying or foregoing care, including skipping surveillance tests, treatment, and follow-up [30, 31].
Kent et al. reported that self-reported financial
problems led to an almost 200% increase in the proportion of survivors who skipped medical care compared to those without financial problems (13.8% vs.
5.0%, respectively) [35].
This study is limited as the cost of care to patients
was not quantified. However, there is often a financial burden for patients to attend clinic visits and
adhering to screening guidelines. Financial cost of
healthcare is a well-known factor contributing to
nonadherence across patient populations, including
cancer survivors [36]. Compared to noncancer peers
and siblings, CCS also have lower socioeconomic attainment, including lower education, higher rates
of under/unemployment, and lower income [37],
which is associated with less use of follow-up medical care [38]. More than half of adult survivors of
childhood cancer report concern about being unable to pay for health care and medication expenses
and 33% report an inability to obtain care due to finances [39]. Within the Childhood Cancer Survivor
Study (CCSS), 25% of survivors had skipped a medical test, treatment, or follow-up care in the past year
because of cost; 28% postponed preventative care;
and 16% did not fill a prescription because of cost
[40]. Forgoing care and nonadherence to surveillance recommendations undermine evidence-based
care for health risk management and jeopardize
CCS’s long-term quality of life [35, 41, 42].
Further work is needed to better understand patient- and system-level factors that impact CCS’s
adherence behaviors and to build supportive care
strategies to improve adherence rates. This may
be particularly important for high-risk patient subgroups.[43] At minimum, efforts must be made to
ensure that patients have an accurate understanding
of health risks and surveillance recommendations,
as misperceptions of susceptibility to late effects
have been reported at high rates [44]. Patients may
also benefit from resources to help them understand
cancer-related finance issues, such as health care
bills and insurance coverage, to help with financial
planning, and to overcome barriers to accessing care
(e.g., low-cost travel arrangements) [45, 46].
Several strategies may be implemented to identify
patients at risk for nonadherence and provide meaningful support. Brief screening tools or question
prompts for providers may feasibly be incorporated
into routine care to identify and triage patients in
need of health system-, community-, or web-based
support resources [39, 47]. Educational and skillsbuilding interventions are needed to help promote
optimal health management and planning among
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patients or to guide patients through complex decisions, such as choosing health insurance plans that
meet their needs. Park et al. [48] conducted in-depth
interviews with CCS about their perceptions and
knowledge of the ACA and found pervasive knowledge deficits and concerns about future health care
costs among both insured and uninsured survivors.
As CCS are at risk for financial barriers to care,
patient-centered financial education courses and
provider- or staff-level training (“financial navigators”) may provide significant benefit in this respect
[49–51]. Resources developed by patient organizations exist to educate and support survivors around
cancer-related financial toxicity, including health insurance selection (e.g., Cancer Financial Assistance
Coalition). Shankaran et al. in partnership with
the Consumer Education and Training Services
(CENTS) and Patient Advocate Foundation (PAF)
developed a financial education course for cancer
patients, aimed to improve knowledge of treatment
costs, provide financial counseling, and assist in
managing out-of-pocket expenses [51, 52]. A recent
systematic review reported that only two of five randomized controlled trials aiming to improve CCS’s
adherence to surveillance guidelines were effective;
both involved telephone outreach, suggesting the importance of clinic resources and adequate personnel
time to make such services feasible within survivorship care programs [53]. Further research is needed
to develop evidence-based resources and to validate
those that already exist to determine their efficacy
in helping patients understand and manage their finances and to support financial decision-making.

hospitals increasingly adopt digital health strategies
for connecting with patients, systems that support
transportable survivorship care and data collection
is critical for clinical and research efforts.
As there are many models of survivorship care
delivery, we may not be able to extrapolate our adherence costs to other programs. Our patient cohort
was also primarily White with commercial insurance
and there was missing data on patient-level factors
due to gaps in data in the electronic medical record.
Missing data were a limitation, particularly, for
race and insurance variables. However, this was accounted for in the analyses by including missingness
into the models (i.e., “Unknown” and “N/A”
categories for race and insurance, respectively) such
that parameter estimates were generated controlling
for missing data. Nevertheless, this presents a limitation to our findings. We were also unable to directly
measure the financial impact of survivorship care on
the patient (e.g., copays and out-of-pocket expenses)
as the actual cost to the survivor is a function of a
patient’s insurance coverage. The insurance data we
incorporated into our analyses were based on estimates and do not reflect individual patients’ cost
burden. Data also do not include hospital-level costs
associated with comorbidities, which further limits
our findings as this patient population is at increased
risk for comorbid health problems. We based our
financial data on health system-specific figures, assuming all CCS had their surveillance procedures
done within our health system. As procedure costs
vary among practice settings, we may not be able to
extrapolate our cost data to other institutions.

Limitations

CONCLUSION

Our study is limited by the relatively small cohort,
in which patients were actively engaged in survivorship care. The relatively short follow-up time period
limited our ability to evaluate the impact of patient
adherence and surveillance on long-term costs or
health outcomes for patients. We also observed that
the proportion of adherent patients increased with
a greater number of visits, whereas the proportion
of nonadherent patients decreased. This may have
been due to: (a) those who are recommended to be
seen more frequently are typically much closer in
time from the end of therapy and may have a heightened concern about their health and/or (b) those
who are seen more often receive more counseling,
are perhaps more educated and vested in their
care, and are more connected to the survivorship
care team. We were unable to obtain data from survivors who did not attend a clinic visit at least once
or who dropped out and findings may be biased
toward those willing and financially able to attend
the clinic, representing a greater likelihood of adherence. Childhood cancer survivors, particularly those
in the young adult age range, are a transient group,
and tracking patients over time can be difficult. As

In conclusion, we believe that dedicated survivorship programs are important in the care of CCS.
Resourcing those programs is challenging, as
they are often loss leaders in that they do not generate revenue for the health system through their
own billing. Nonetheless, CCS undergo multiple
screening tests, all of which are revenue generating
and would likely not be performed within the health
system if not for the presence of the survivorship
program. As such, while it can be uncomfortable, it
is important to highlight the fiscal contributions of
survivorship programs to the health system to justify
resourcing them most appropriately. To that end,
we have identified the cost of care as a factor associated with adherence in CCS, and that adherence is,
in turn, associated with a better financial outcome
for the health system. This relationship suggests that
finding ways to improve adherence to care among
CCS would be mutually beneficial to the patient
and the health system. Some possibilities include
the establishment of financial coordinators who can
improve access for CCS to materials and education
surrounding insurance options and managing outof-pocket expenses, improving the coordination of
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screening tests to reduce days of missed work and
travel expenses, and supporting research in understanding the barriers CCS face in adhering to
screening recommendations.
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